- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05697523
Multiple Sclerosis and Respiratory and Functional Capacity
Comparison of Respiratory, Physical Activity and Functional Capacities of Patients wıth Mild Relapsing Remitting Multiple Sclerosis and Healthy Controls
Study Overview
Status
Conditions
Detailed Description
It is known that respiratory functions, physical activities and functional capacities of Multiple Sclerosis (MS) patients decrease with the progression of the disease. However, there is not enough information about the severity of the effects of these parameters in mild Relapsing-Remitting Multiple Sclerosis (RRMS) patients. Our aim in this study is to compare the respiratory functions, physical activities and functional capacities of mild RRMS patients with healthy controls and to examine the relationship between them.
Forty individuals diagnosed with RRMS between the ages of 18-60 and 40 healthy individuals with similar demographic characteristics were included in the study.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Denizli, Turkey, 20200
- Pamukkale University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Patient group - Inclusion Criteria:
- Having a definitive diagnosis of RRMS according to the 2017 McDonald criteria
- Being between the ages of 18-60.
- To be willing to participate in the study.
- EDSS score between 0-3.
Healthy group - Inclusion Criteria:
- Being between the ages of 18-60.
- To be willing to participate in the study.
Patient group - Exclusion Criteria:
- Have other neurological, orthopedic and systemic problems
- Having a relapse 30 days before or during the study
- Changes in medication use in the past 30 days
Healthy group - Exclusion Criteria:
- Have neurological, orthopedic and systemic problems
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patient group
people with mild RRMS
|
Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test
|
Healthy group
healthy people
|
Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pulmonary Function Tests- FEV1/FVC
Time Frame: Baseline
|
Evaluation of FEV1/FVC ratio MicroQuark® computer-based USB spirometer will be used to assess the respiratory function of the participants.
The person will be asked to take a few normal breaths followed by as deep a breath as possible and instructed to exhale forcefully and quickly without waiting.
The test will be terminated by instructing the participant to take a deep breath after exhaling for at least six seconds.
|
Baseline
|
Pulmonary Function Tests- FVC
Time Frame: Baseline
|
Evaluation of Forced Vital Capacity (FVC) MicroQuark® computer-based USB spirometer will be used for FVC evaluation.
The person will be asked to take a few normal breaths, then take as deep a breath as possible, and then exhale forcefully and quickly without waiting.
The test will be terminated by instructing the participant to take a deep breath after exhaling for at least six seconds.
|
Baseline
|
Pulmonary Function Tests- FEV1
Time Frame: Baseline
|
Evaluation of Forced Expiratory Volume in 1 second (FEV1) MicroQuark® computer-based USB spirometer will be used for FEV1 evaluation.
The person will be asked to take a few normal breaths, then take as deep a breath as possible, and then exhale forcefully and quickly without waiting.
The test will be terminated by instructing the participant to take a deep breath after exhaling for at least six seconds.
|
Baseline
|
Pulmonary Function Tests- PEF
Time Frame: Baseline
|
Evaluation of Peak Expiratory Flow (PEF) MicroQuark® computer-based USB spirometer will be used for PEF evaluation.
The person will be asked to take a few normal breaths, then take as deep a breath as possible, and then exhale forcefully and quickly without waiting.
The test will be terminated by instructing the participant to take a deep breath after exhaling for at least six seconds.
|
Baseline
|
Pulmonary Function Tests- MVV
Time Frame: Baseline
|
Maximum voluntary ventilation (MVV) MicroQuark® computer-based USB spirometer will be used for MVV evaluation.
Then the participant will take the disposable bacteria filter mouthpiece between his lips and holds it tightly.
The person will be asked to deeply and rapidly breaths for 10 to 15 seconds.
|
Baseline
|
Functional Capacity
Time Frame: Baseline
|
The 6-minute walk test (6MWT) was used to measure functional capacity.
In the test, the participant was asked to walk for 6 minutes as fast as possible in a 30-meter corridor, and the total distance in meters was recorded.
Standard encouragement was given to the participant every 60 seconds during the test.
Estimated values of participants For men; (7.57
x height(cm)) - (5.02 x age) - (1.76 x kg) - 309, for women; Calculated with the formula (2.11 x height(cm)) - (2.29 x kg) - (5.78 x age) + 667.
|
Baseline
|
International Physical Activity Questionnaire - Short Form
Time Frame: Baseline
|
The International Physical Activity Questionnaire-Short Form (IPAQ-SF) was used to evaluate physical activity.
It was developed to evaluate the physical activities of people between the ages of 15-60 in their daily lives.
It consists of seven questions in total and questions the time spent in vigorous, moderate-to-severe and walking activities.
In addition, the sitting time is considered as a separate question.
The Metabolic Equivalent (MET-minute) score is determined at the end of the calculation made by multiplying the MET value of the activities performed by the minute.
Classification is based on the numerical data obtained.
Accordingly, there are 3 activity levels: Inactive, minimal active and very active.
The lowest level of physical activity is inactive and the highest level of physical activity is very active.
The IPAQ is a valid and reliable test in MS patients.
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Expanded Disability Status Scale
Time Frame: Baseline
|
The Expanded Disability Status Scale is a method of quantifying disability in multiple sclerosis.
The scale is based on a neurological examination by a clinician.
It has steps from 0 to 10.
The higher scores indicate higher neurological disability.
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 60116787-020/92286
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test
-
Saglik Bilimleri UniversitesiNot yet recruitingPes Planus
-
Istanbul Kültür UniversityMarmara University; Istanbul University - Cerrahpasa (IUC)CompletedPhysical Activity | Parkinson Disease | Balance | Falling | KinesiophobiaTurkey
-
Children's Hospital Los AngelesRecruitingQuality of Life | Respiration Disorders | Ventilator-Induced Lung Injury | Respiratory Distress Syndrome, Adult | Neurocognitive DysfunctionUnited States
-
Maria Cecilia HospitalNot yet recruitingCardiovascular Prevention
-
University of FloridaUniversity of South Florida; National Institute of Neurological Disorders and...CompletedSpinocerebellar AtaxiaUnited States
-
MeLSyTech, LtdCompletedUrinary Incontinence | Sexual Dysfunction | Vaginal Atrophy | Postoperative Care | Preoperative Care | Female Urogenital Diseases | Menopausal Syndrome | Prolapse Genital | Postpartum Period | Postmenopausal Period | Vaginal ProlapseRussian Federation
-
Brunel UniversityUniversity of Sao PauloUnknownBreathlessness | Hyperventilation Syndrome | Respiration Disorder | Breath ShortnessUnited Kingdom
-
Hacettepe UniversityCompletedQuality of Life | Physical Disability | Psychosocial Problem | Meniere DiseaseTurkey
-
University Hospital, EssenBristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme LLC; Boehringer Ingelheim and other collaboratorsCompletedHeart Failure | Metabolic Syndrome | HIV | Coronary Heart Disease | AIDSGermany
-
Universidade Estadual de LondrinaUniversidade Norte do ParanáRecruitingInterstitial Lung DiseaseBrazil